INTRODUCTION
The first inoculations of inactivated hepatitis B vaccine were administered to 11 adult volunteers in November 1975. Since that time many millions of infants, children, and adults worldwide have been immunized with various plasma-derived vaccines. Experience during the past ten years has confirmed the safety, immunogenicity, and efficacy of these vaccines [1] [2] [3] [4] .
The development of an inactivated hepatitis B vaccine and its licensure in the United States in November 1981 was an important milestone in the history of preventive medicine. The technology that led to the development of the vaccine also led to the development of specific, sensitive tests for the detection of markers for hepatitis B virus (HBV) infection. Seroepidemiological surveys by many investigators confirmed that hepatitis B was a major public health problem in most countries of the world.
The seroepidemiological surveys have revealed that about 200 million persons worldwide are asymptomatic HBV carriers. In addition, HBV-related hepatoma is the most common malignant tumor in many Asian and African countries, accounting for 20 to 40 percent of all cancer deaths among men in these areas. In contrast, hepatoma is responsible for only 2 percent of malignant tumors in the United States.
Although hepatitis is less prevalent in the United States, its toll is still significant. The Centers for Disease Control has estimated that about 200,000 HBV infections occur each year. Of these, about 50,000 persons have clinically recognizable disease with jaundice, about 10,000 may require hospitalization, and about 10,000 to 20,000 will become chronic HBV carriers. In addition, about 40,000 persons will die of HBV-related cirrhosis and about 800 deaths will be caused by HBV-related cancer of the liver. These impressive statistics highlight the need for an effective hepatitis B vaccine.
DEVELOPMENT OF HEPATITIS B VACCINE

Plasma-Derived Vaccines
The chronological events that led to the development of hepatitis B vaccine began in 1965 with the report of the discovery of the Australia antigen by Blumberg et al. [5] and its subsequent association with hepatitis B by Prince [6] and by Giles et al. [7] . In 1970 Dane et al. [8] identified by immune electron microscopy 42 nm double-shelled, virus-like particles in the serum of patients with Australia antigen-associated hepatitis. Later, it became apparent that the "Dane particle" was the hepatitis B virion. It also became apparent that Australia antigen was immunologically identical with the surface component of HBV and with the 20 nm particles present; it was immunologically distinct from the core component of HBV. Therefore, Australia antigen was designated as hepatitis B surface antigen (HBsAg), and the core component was designated as hepatitis B core antigen (HBcAg).
In 1970 Krugman et al. demonstrated that the inactivated HBV serum (MS-2 strain), which contained large quantities of HBsAg as well as the virus, was not infectious but it was antigenic [9] . The detection of antibody to HBsAg (anti-HBs) in the serum of recipients of the heat-inactivated MS-2 serum indicated that the non-infectious HBsAg particle was the antigen needed for vaccine production. In subsequent studies we demonstrated that heat-inactivated MS-2 serum was immunogenic and partially protective [10] .
Vaccine development was accelerated in 1972 and 1973 when hepatitis B was successfully transmitted to non-human primates [11] . Seronegative chimpanzees proved to be excellent animal models for the study of HBV infection and for the safety-testing of hepatitis B vaccines. In addition, the development of sensitive assays to detect markers of HBV infection (HBsAg, anti-HBs, anti-HBc [hepatitis B core antibody], HBeAg [hepatitis B e antigen], and anti-HBe [antibody to HBeAg]) provided reliable indicators of vaccine safety and immunogenicity. By the mid-1970s several investigators had prepared inactivated hepatitis B vaccines from purified preparations of HBsAg [12, 13] . The source of the antigen was HBsAg-positive plasma from chronic carriers.
The preparation of the plasma-derived vaccine that is manufactured and licensed in the United States involves a series of complex physical and chemical procedures to isolate the 20 nm spherical HBsAg particles. These procedures include three separate inactivation steps: pepsin at pH2, 8 M urea, and a 1:4,000 dilution of formalin. Each of these steps has been shown to inactivate the following viruses that may be present in blood: HBV; non-A, non-B hepatitis virus; herpesviruses; and human immunodeficiency virus (HIV).
Recombinant Hepatitis B Vaccine
The use of DNA recombinant technology has enabled investigators to synthesize HBsAg in cells of baker's yeast, Saccharomyces cervisiae. The final purified HBsAg particles have close structural and biochemical similarities to particles derived from plasma of chronic HBsAg-positive carriers [14] . Studies by various investigators have confirmed the safety, immunogenicity, and efficacy of the yeast recombinant hepatitis B vaccine prepared by Merck, Sharp and Dohme [15] .
Studies of Vaccine-Induced Immunity
The duration of vaccine-induced immunity was studied in a group of 54 seronegative health professionals in 1978 and 1979. Initially they received 20 ,ug doses of Merck plasma-derived vaccine at zero, one, two, and nine months. Subsequently serum specimens were obtained one year and five to seven years after primary immunization. The sera were tested for anti-HBs by solid radioimmunoassay (Ausab; Abbott Laboratories, North Chicago, IL). The anti-HBs test results were calculated as the ratio of sample counts per minute (cpm) to the mean negative control cpm (S/N), with values of >2.1 considered positive.
A 10 Mg booster dose of yeast recombinant vaccine was given to 52 of the 54 vaccinees five to seven years after the initial immunization. The results of serial tests for anti-HBs one year after the primary immunization and 2, 4, and 26 weeks after the booster dose are shown in Table 1 . Two vaccinees (numbers 53 and 54) did not receive a booster dose because they contracted hepatitis B with jaundice five years after the initial immunization.
A review of the data listed in Table 1 reveals the following findings:
1. Of 54 vaccinees, 47 (87 percent) had a favorable antibody response (10-477 S/N) one year after primary vaccination, 4 (8 percent) had low levels of anti-HBs (2.1-10 S/N), and 3 (5 percent) had no detectable anti-HBs (<2.1 S/N).
2. The anti-HBs status of 52 vaccinees five to seven years after the primary immunization was as follows: 13 (25 percent) had no detectable antibody; 12 (23 percent) had low levels (2.1-10 S/N) and 27 (52 percent) had favorable levels (>10 S/N).
3. After the booster dose of vaccine an anamnestic response at two to four weeks was detected in 47 (90 percent) of the vaccinees. There were five poor or nonresponders (numbers 3, 7, 9, 1 1, and 12).
4. The two vaccinees who contracted hepatitis B five years after primary immunization were poor (number 53) or non-responders (number 54).
The induction of an anamnestic response five to seven years after successful primary immunization was very encouraging. High levels of antibody by two weeks were observed in most vaccinees who had low or undetectable levels of anti-HBs before receiving the booster dose. This finding is reassuring because the incubation period of hepatitis B usually exceeds six weeks. Therefore, immunologically primed vaccinees should be protected following exposure to HBV. The induction of an anamnestic response during the early phase of the incubation period should prevent or modify hepatitis B infection. In addition, this type of asymptomatic HBV infection should be followed by lasting immunity.
Long-term follow-up studies by Stevens et al. [16] revealed evidence of a prolonged protective effect of hepatitis B vaccine in high-risk homosexual men who participated in their efficacy trial. Of 455 men who received plasma-derived vaccine at zero, one, and six months, 444 (97.5 percent) had an anti-HBs response and 11 (2.5 percent) were non-responders. During the four-to five-year follow-up period, 28 hepatitis B infections occurred among the 455 men. Of the 28 infections, 25 (89 percent) were inapparent. These inapparent infections were characterized by absence of symptoms, normal ALT values, no detectable HBsAg, a boost in anti-HBs values, and seroconver- 9  37  10  41  11  46  12  74  13  47  14  54  15  36  16  44  17  59  18  40  19  39  20  64  21  46  22  30  23  34  24  49  25  41  26  34  27  35  28  38  29  45  30  74  31  28  32  49  33  43  34  33  35  31  36  34  37  40  38  34  39  38  40  35  41  41  42  52  43  38  44  34  45  30  46  42  47  35 The results of the present study and the study by Stevens et al. [16] indicate that successfully immunized persons may be protected for as long as seven years after primary immunization with inactivated hepatitis B vaccine. It is likely that persons who respond to primary immunization will have long-lasting immunity.
